LEADER 01818nlm0 22005051i 450 001 990009237860403321 010 $a9783540457008 035 $a000923786 035 $aFED01000923786 035 $a(Aleph)000923786FED01 035 $a000923786 100 $a20100926d2006----km-y0itay50------ba 101 0 $aeng 102 $aDE 135 $adrnn-008mamaa 200 1 $aAccessing Multilingual Information Repositories$bRisorsa elettronica$e6th Workshop of the Cross-Language Evalution Forum, CLEF 2005, Vienna, Austria, 21-23 September, 2005, Revised Selected Papers$fedited by Carol Peters, Fredric C. Gey, J 210 $aBerlin ; Heidelberg$cSpringer$d2006 225 1 $aLecture Notes in Computer Science$x0302-9743$v4022 230 $aDocumento elettronico 336 $aTesto 337 $aFormato html, pdf 702 1$aGey,$bFredric C. 702 1$aGonzalo,$bJulio 702 1$aJones,$bGareth J. F. 702 1$aKluck,$bMichael 702 1$aMagnini,$bBernardo 702 1$aMüller,$bHenning 702 1$aPeters,$bCarol 702 1$aRijke,$bMaarten 801 0$aIT$bUNINA$gREICAT$2UNIMARC 856 4 $zFull text per gli utenti Federico II$uhttp://dx.doi.org/10.1007/11878773 901 $aEB 912 $a990009237860403321 961 $aArtificial intelligence 961 $aArtificial Intelligence (incl. Robotics) 961 $aComputer science 961 $aComputer Science 961 $aInformation Storage and Retrieval 961 $aInformation storage and retrieval systems 961 $aInformation systems 961 $aInformation Systems Applications (incl.Internet) 961 $aLanguage Translation and Linguistics 961 $aTranslators (Computer programs) 996 $aAccessing Multilingual Information Repositories$9772621 997 $aUNINA LEADER 05601nam 2200733 450 001 9910816425603321 005 20200520144314.0 010 $a1-118-69789-8 010 $a1-118-69719-7 010 $a1-118-69791-X 035 $a(CKB)3710000000106462 035 $a(EBL)1683802 035 $a(SSID)ssj0001195731 035 $a(PQKBManifestationID)11703175 035 $a(PQKBTitleCode)TC0001195731 035 $a(PQKBWorkID)11161113 035 $a(PQKB)10802183 035 $a(OCoLC)867001315 035 $a(MiAaPQ)EBC1683802 035 $a(DLC) 2013051083 035 $a(Au-PeEL)EBL1683802 035 $a(CaPaEBR)ebr10867125 035 $a(CaONFJC)MIL604408 035 $a(OCoLC)879074476 035 $a(PPN)190664223 035 $a(EXLCZ)993710000000106462 100 $a20140515h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aLigand design in medicinal inorganic chemistry /$fedited by Tim Storr ; contributors Peter J. Barnard [and thirty seven others] 210 1$aChichester, England :$cWiley,$d2014. 210 4$dİ2014 215 $a1 online resource (493 p.) 300 $aDescription based upon print version of record. 311 $a1-118-48852-0 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover; Title Page; Copyright; Contents; About the Editor; List of Contributors; Chapter 1 Introduction to Ligand Design in Medicinal Inorganic Chemistry; References; Chapter 2 Platinum-Based Anticancer Agents; 2.1 Introduction; 2.2 The advent of platinum-based anticancer agents; 2.3 Strategies for overcoming the limitations of cisplatin; 2.4 The influence of ligands on the physicochemical properties of platinum anticancer complexes; 2.4.1 Lipophilicity; 2.4.2 Reactivity; 2.4.3 Rate of reduction; 2.5 Ligands for enhancing the anticancer activity of platinum complexes 327 $a2.5.1 Ligands for improving DNA affinity2.5.2 Ligands for inhibiting enzymes; 2.6 Ligands for enhancing the tumour selectivity of platinum complexes; 2.6.1 Ligands for targeting transporters; 2.6.2 Ligands for targeting receptors; 2.6.3 Ligands for targeting the EPR effect; 2.6.4 Ligands for targeting bone cancer; 2.7 Ligands for photoactivatable platinum complexes; 2.8 Conclusions; References; Chapter 3 Coordination Chemistry and Ligand Design in the Development of Metal Based Radiopharmaceuticals; 3.1 Introduction; 3.1.1 Metals in nuclear medicine 327 $a3.1.2 The importance of coordination chemistry3.1.3 Overview; 3.2 General metal based radiopharmaceutical design; 3.2.1 Choice of radionuclide; 3.2.2 Production of the radiometal starting materials; 3.2.3 Ligand and chelate design consideration; 3.3 Survey of the coordination chemistry of radiometals applicable to nuclear medicine; 3.3.1 Technetium; 3.3.2 Rhenium; 3.3.3 Gallium; 3.3.4 Indium; 3.3.5 Yttrium and lanthanides; 3.3.6 Copper; 3.3.7 Zirconium; 3.3.8 Scandium; 3.3.9 Cobalt; 3.4 Conclusions; References; Chapter 4 Ligand Design in d-Block Optical Imaging Agents and Sensors 327 $a4.1 Summary and scope4.2 Introduction; 4.2.1 Criteria for biological imaging optical probes; 4.3 Overview of transition-metal optical probes in biomedicinal applications; 4.3.1 Common families of transition metal probes; 4.4 Ligand design for controlling photophysics; 4.4.1 Photophysical processes in transition metal optical imaging agents and sensors; 4.4.2 Photophysically active ligand families-tuning electronic levels; 4.4.3 Ligands which control photophysics through indirect effects; 4.4.4 Transition metal optical probes with carbonyl ligands; 4.5 Ligand design for controlling stability 327 $a4.6 Ligand design for controlling transport and localisation4.6.1 Passive diffusion; 4.6.2 Active transport; 4.7 Ligand design for controlling distribution; 4.7.1 Mitochondrial-targeting probes; 4.7.2 Nuclear-targeting probes; 4.7.3 Bioconjugation; 4.8 Selected examples of ligand design for important individual probes; 4.8.1 A pH-sensitive ligand to control Ir luminescence; 4.8.2 Dimeric NHC ligands for gold cyclophanes; 4.9 Transition metal probes incorporating or capable of more than one imaging mode; 4.9.1 Bimodal MRI/optical probes; 4.9.2 Bimodal radio/optical probes 327 $a4.9.3 Bimodal IR/optical probes 330 $aIncreasing the potency of therapeutic compounds, while limiting side-effects, is a common goal in medicinal chemistry. Ligands that effectively bind metal ions and also include specific features to enhance targeting, reporting, and overall efficacy are driving innovation in areas of disease diagnosis and therapy. Ligand Design in Medicinal Inorganic Chemistry presents the state-of-the-art in ligand design for medicinal inorganic chemistry applications. Each individual chapter describes and explores the application of compounds that either target a disease site, or are activated 606 $aDNA-drug interactions 606 $aLigand binding (Biochemistry) 606 $aDrugs$xDesign 606 $aPharmaceutical chemistry 615 0$aDNA-drug interactions. 615 0$aLigand binding (Biochemistry) 615 0$aDrugs$xDesign. 615 0$aPharmaceutical chemistry. 676 $a612/.01524 702 $aStorr$b Tim 702 $aBarnard$b Peter J. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910816425603321 996 $aLigand design in medicinal inorganic chemistry$93943206 997 $aUNINA